You are here: Industry Insights > Immunocore

News List

Immunocore’s Lead Asset Tebentafusp Gains Fast Track Designation for Metastatic Uveal Melanoma drugs
April 17, 2019
Immunocore’s Lead Asset Tebentafusp Gains Fast Track Designation for Metastatic Uveal Melanoma.
Immunocore appoints David Berman as R&D chief firstwordpharma
January 16, 2019
Prior to joining Immunocore, Berman served as senior vice president and head of AstraZeneca's immuno-oncology franchise, holding responsibility for the strategy and execution of the drugmaker's late-stage immuno-oncology programme.
Amid Immunocore’s C-suite bloodletting Glaxo provides solace evaluate
August 21, 2018
Three years after closing a record-breaking $320m private financing Immunocore is having a personnel crisis. The shock departure in February of its chief executive, Eliot Forster, has had a contagious effect, with various other execs, including chief medi
Gates Foundation invest in Immunocore, warning of infectious disease threat pharmafile
September 21, 2017
It has been announced that the Bill & Melina Gates Foundation will invest up to $40 million in UK-based Immunocore to support the development of therapeutics for infectious diseases.